Zobrazeno 1 - 10
of 186
pro vyhledávání: '"G, Koschel"'
Autor:
J Dethling, R. Lorenz, U. Seifart, K Hans, T Fink, M. Wolf, Carmen Schade-Brittinger, G. Koschel, H. Schroeder, C. Mueller
Publikováno v:
Annals of Oncology. 18:104-109
Background: Topotecan is an active drug in small-cell lung cancer (SCLC). In our previous study, a combination of topotecan with cisplatin was associated with a median overall survival of 7.6 or 8.7 months, depending on the duration of treatment. We
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::c4b600509671a3fad90e1534ec83c695
https://doi.org/10.1093/annonc/mdl353
https://doi.org/10.1093/annonc/mdl353
Autor:
K. Dalhoff, U. Gatzemeier, E.-M. Ehlers, R Zumschlinge, S.O. Peters, G. J. Wiedemann, Th. Kohlmann, K. Eberhardt, S. Hegewisch-Becker, A Demedts, I. Bruns, Y Gruber, H.I Robins, E. Kaukel, G. Koschel, A. Bakhshandeh, Anne M. Traynor
Publikováno v:
Lung Cancer. 39:339-345
We performed a phase II study combining 41.8 degrees C whole body hyperthermia with ICE chemotherapy, i.e. ifosfamide (5 g/m(2)), carboplatin (300 mg/m(2)) and etoposide (150 mg/m(2) on days 2 and 3), administered every 4 weeks, for patients with mal
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::a93ea1e3ea439060ebd2dcec939fb7ca
https://doi.org/10.1016/s0169-5002(02)00536-6
https://doi.org/10.1016/s0169-5002(02)00536-6
Autor:
E. Kaukel, Sybill Hessler, Ulrich Gatzemeier, G. Koschel, Franziska Grunwald, Martin Reck, Joachim von Pawel, Urzula Jagos
Publikováno v:
Lung Cancer. 39:63-69
Purpose: We evaluated the toxicity and feasibility of adding paclitaxel to a standard platinum/etoposide regimen in the first-line treatment of patients with small cell lung cancer (SCLC). Patients and methods: Eighty-nine patients with limited disea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::5c03a088dc4c74f61671b7a7edc8988d
https://doi.org/10.1016/s0169-5002(02)00383-5
https://doi.org/10.1016/s0169-5002(02)00383-5
Autor:
W Pfeifer, G. Koschel, J. Frisch, M. von Eiff, Nick Thatcher, William P. Steward, R. de Wit, J Fennelly, J. von Pawel, U. Gatzemeier, Penella J. Woll, Jaap Verweij, Luke Clancy
Publikováno v:
Scopus-Elsevier
Journal of Clinical Oncology, 16(2), 642-650. American Society of Clinical Oncology
Europe PubMed Central
Journal of Clinical Oncology, 16(2), 642-650. American Society of Clinical Oncology
Europe PubMed Central
PURPOSE To assess whether granulocyte-macrophage colony-stimulating factor (GM-CSF) reduces the toxicity of chemotherapy and alters delivered dose-intensity. To assess the feasibility of dose-intensification of chemotherapy in small-cell lung cancer
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d648c37afe6531c1b9137e6751b04963
https://doi.org/10.1200/jco.1998.16.2.642
https://doi.org/10.1200/jco.1998.16.2.642
Autor:
Gorina, Daria S.1,2 (AUTHOR) d.gorina@g.nsu.ru, Lastovka, Anastasiya V.1,2 (AUTHOR) lastovka@nioch.nsc.ru, Rogachev, Artem D.1,2 (AUTHOR) podturkina@nioch.nsc.ru, Podturkina, Alexandra V.1 (AUTHOR) pavlova@nioch.nsc.ru, Pavlova, Alla V.1 (AUTHOR) ardashov@nioch.nsc.ru, Ardashov, Oleg V.1 (AUTHOR) lizhulan@nioch.nsc.ru, Li-Zhulanov, Nikolai S.1 (AUTHOR) tg_tolstikova@mail.ru, Tolstikova, Tatyana G.1 (AUTHOR) volcho@nioch.nsc.ru, Volcho, Konstantin P.1 (AUTHOR) anvar@nioch.nsc.ru, Salakhutdinov, Nariman F.1 (AUTHOR)
Publikováno v:
Molecules. Sep2024, Vol. 29 Issue 18, p4498. 17p.
Publikováno v:
Cancer. 66:651-654
Thirty-five non-pretreated patients (29 male, six female) with malignant pleural mesothelioma, median age of 68.5 years (range, 29 to 78 years) and a median performance status of 80% (range, 60% to 100%) were treated with 70 mg/m2 Pirarubicin. The tr
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::6f3807c1c657c4fc7107482279f707fd
https://doi.org/10.1002/1097-0142(19900815)66:4<651::aid-cncr2820660408>3.0.co
https://doi.org/10.1002/1097-0142(19900815)66:4<651::aid-cncr2820660408>3.0.co
Autor:
G. J. Penzl, K. Dalhoff, S.O. Peters, P. Zabel, S. Hegewisch-Becker, R. Zumsclinge, G. J. Wiedemann, A. Bakhshandeh-Bath, U. Gatzemeier, G. Koschel
Publikováno v:
Pneumologie. 58
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_________::56d20df7fd6faefb780de2c5682b8215
https://doi.org/10.1055/s-2004-819737
https://doi.org/10.1055/s-2004-819737
Publikováno v:
Pneumologie (Stuttgart, Germany). 52(10)
In the palliative treatment of advanced SCLC and NSCLC there is a big need for effective and well tolerable drugs. Bendamustin is an alcylatic agent which had shown activity in the treatment of Non Hodgkin- and Hodgkin-Lymphoma as well as in the trea
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::a9ea36124a0b45053987b66caa44913c
https://pubmed.ncbi.nlm.nih.gov/9847635
https://pubmed.ncbi.nlm.nih.gov/9847635
Publikováno v:
Seminars in oncology. 24(4 Suppl 12)
Carboplatin/etoposide is an active regimen in the treatment of small cell lung cancer. This phase II trial evaluated whether adding paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) to this two-drug combination might increase its effica
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::639857fc1d6025a4c3e17bce5eb4328c
https://pubmed.ncbi.nlm.nih.gov/9331141
https://pubmed.ncbi.nlm.nih.gov/9331141
Publikováno v:
Seminars in oncology. 23(5 Suppl 12)
We performed a clinical phase II trial of the combination of paclitaxel (Taxol; Bristol-Myers Squibb Company, Princeton, NJ) and cisplatin in patients with locally advanced (stage IIIB) or metastatic non-small cell lung cancer (NSCLC), using a 3-hour
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=pmid________::f4204ab49ae95b8ba664df4bebe4a0fc
https://pubmed.ncbi.nlm.nih.gov/8941403
https://pubmed.ncbi.nlm.nih.gov/8941403